These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
587 related articles for article (PubMed ID: 33824975)
1. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975 [TBL] [Abstract][Full Text] [Related]
2. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592 [TBL] [Abstract][Full Text] [Related]
3. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012 [TBL] [Abstract][Full Text] [Related]
4. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
5. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Ewald L; Dittmann J; Vogler M; Fulda S Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941 [TBL] [Abstract][Full Text] [Related]
6. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. Al-Zebeeby A; Vogler M; Milani M; Richards C; Alotibi A; Greaves G; Dyer MJS; Cohen GM; Varadarajan S Haematologica; 2019 May; 104(5):1016-1025. PubMed ID: 30467206 [TBL] [Abstract][Full Text] [Related]
7. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. Besbes S; Pocard M; Mirshahi M; Billard C Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021 [TBL] [Abstract][Full Text] [Related]
8. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511 [TBL] [Abstract][Full Text] [Related]
9. Pathways and mechanisms of venetoclax resistance. Bose P; Gandhi V; Konopleva M Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720 [TBL] [Abstract][Full Text] [Related]
10. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Carter BZ; Mak PY; Tao W; Ayoub E; Ostermann LB; Huang X; Loghavi S; Boettcher S; Nishida Y; Ruvolo V; Hughes PE; Morrow PK; Haferlach T; Kornblau S; Muftuoglu M; Andreeff M Blood Cancer J; 2023 Apr; 13(1):57. PubMed ID: 37088806 [TBL] [Abstract][Full Text] [Related]
12. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070 [TBL] [Abstract][Full Text] [Related]
13. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887 [TBL] [Abstract][Full Text] [Related]
14. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163 [TBL] [Abstract][Full Text] [Related]
15. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249 [TBL] [Abstract][Full Text] [Related]
16. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
17. A BH3 Mimetic for Killing Cancer Cells. Green DR Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468 [TBL] [Abstract][Full Text] [Related]
18. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Merino D; Lok SW; Visvader JE; Lindeman GJ Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067 [TBL] [Abstract][Full Text] [Related]
19. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407 [TBL] [Abstract][Full Text] [Related]